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Recently, we purified a new mouse T cell-derived lymphokine that we provi-
sionally designated interleukin-HPI (HPI)' because of its growth factor activity
for B cell hybridomas and plasmacytomas (1, 2) . This factor, which was identi-
fied as a single chain 25-30-kD polypeptide, was subsequently found to be struc-
turally and serologically indistinguishable from the plasmacytoma growth factors
produced by macrophages and fibroblasts (3-5). Molecular cloning and
sequencing of HPI cDNA (6) disclosed a very significant degree of homology
with the human hybridoma growth factor, now termed interleukin 6 (7-8), that
we had previously found to be identical (9) with B cell stimulatory factor 2 (10),
26-kD protein (11) and IFN-,82 (12), and that has now also been identified with
the monocyte-derived hepatocyte-stimulating factor (13) .
To evaluate the role of HPI/IL-6 in the immune system, we have started to
investigate how this molecule affected the response of normal mouse lympho-
cytes to various stimuli . Recently, we showed that (14) in the presence of IL-1,
HPI/IL-6 represented a major stimulus for B cell growth and differentiation .
A salient finding of these studies was the observation that the combination of
IL-1 and HP1/IL-6 induced B cell responses comparable in many respects to
those obtained with established B cell growth and differentiation factors like IL-
4 and IL-5 .
In the present report we show that HPI/IL-6 also stimulates T cell growth
and differentiation, and we provide evidence suggesting that production of this
molecule is one of the mechanisms through which accessory cells support poly-
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T Cell Proliferation Assays.
￿
Spleen cells and mesenteric lymph node cells from 10-wk-
old female BALB/c mice were cultured in flat-bottomed microtiter wells at a cell density
of 3-5 X 104 cells/well in DME supplemented with 10% FCS, L-arginine (0.55 MM), L-
asparagine (0.24 HIM), L-glutamine (1 .5 mM), and 2-ME (50 AM). To these cultures we
added a costimulator, usually PHA, and the cytokine to be tested. Thymidine incorpo-
ration was measured in triplicate cultures on day 4 after a 6-h pulse with 0.5 pCi methyl-
[3H] thymidine. Optimal responses to HP1/IL-6 required the use of a selected batch of
PHA. The best results were obtained with PHA from Difco Laboratories Inc. (Detroit,
MI) added at a final dilution of 0.5-1 X 10 -'. The response of thymocytes was studied
under similar conditions except that we used 6-wk-old mice, a 2 X 10-s dilution of PHA,
and higher cell numbers (1 .5 X 106 for IL-1 and 0.5 X 106 for IL-2 and HP1/IL-6).
Moreover, the incubation period was reduced to 3 d.
Accessory Cell Depletion. Accessory cell depletion was obtained by passage through
nylon-wool columns as described (15) and treatment with anti-I-Ad antibody MKD-6 (16)
and rabbit complement (Cedarlane Laboratories, Ltd., Hornby, Ontario, Canada).
Induction of Cytolytic T Cell Responses.
￿
C57BL/6 (H-2°) spleen cells were incubated, in
2 ml of DME supplemented as described above, with 2 X 106 irradiated DBA/2 (H-2d)
high-density spleen cells selected by Percoll gradient centrifugation (1 .070 < p <1 .088).
This procedure was adopted to reduce the number of macrophages and thus the levels
of endogenous HP1/IL-6 in the cultures. Cytolytic activity was measured in a conven-
tional chromium-release assay using P815 mastocytoma (H-2d) and EL 4 thymoma (H-
26) as target cells.
Helper T Cell Lines.
￿
Helper T cell lines were established from mice immunized with
keyhole limpet hemocyanin or human transferrin as described (1) . The cell lines were
routinely grown with irradiated spleen cells and antigen but without addition of exoge-
nous growth factors. Before use in proliferation assays, the T cells were separated from
dead cells by centrifugation over a layer of Lymphoprep (Nycomed, Oslo, Norway).
Cytokines.
￿
Human rIL-la (17) and IL-2 (18) were gifts of Drs. P. Lomedico (Roche
Research Center, Nutley, NJ) and W. Fiers (State University of Ghent, Belgium), respec-
tively. HP1/IL-6 and L929-derived hybridoma growth factor (L-HGF) were purified to
homogeneity as described earlier (1, 4) . IL-4 was partially purified from the supernatant
of mouse helper T cell clone TUC2.15 by adsorption on silicic acid, gel filtration, anion
exchange, and reversed-phase HPLC. For each cytokine, 1 U of activity was defined as
the amount of material required to produce half-maximal proliferation of the appropri-
ate target cell, i.e., hybridoma 7TD1 for HP1/IL-6 (1), Cytolytic T cell line CTLL for IL-
2 (19), and anti-IgM-stimulated B cells for IL-4. These assays were carried out as pre-
viously described (1, 2).
Monoclonal Antibodies.
￿
Anti-IL-4 mAb 111111 (20) was a gift of Dr. W. E. Paul (Lab-
oratory of Immunology, National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Bethesda, MD). Anti-HP1/IL-6 mAb 6114 was produced in our lab-
oratory (14). Anti-T cell mAbs used included: (a) anti-Thy-1 .2 antibody 3A8 also pro-
duced in our laboratory, (b) anti-T& antibody 145-2C I I (a gift of Dr. O. Leo, Laboratory
of Animal Physiology, University of Brussels, Belgium) (21), and (c) anti-L3T4 antibody
GK1 .5 (22) and anti-Lyt-2 antibody 53.6.72 (23). All rat mAbs were purified by affin-
ity chromatography using mouse anti-rat is antibody MARKI (24), a gift of Dr. H.




Spleen cells and thymocytes were labeled with fluoresceinated GKl .5
and biotinylated 53.6.72 for 45 min at 4° C in 137 mM NaCl, 5 mM KCI, 0.4 mM
MgS04, 0 .3 mM MgC12, 5 mM glucose, 4 mM NaHCOj, 1 mM EDTA, containing peni-
cillin (500 U/ml), streptomycin (1 pg/ml), and 5% FCS, and buffered with 1 mM phos-
phate (pH 7.4). After centrifugation, the cells were resuspended in the same medium
containing phycoerythrin-conjugated streptavidin (Becton Dickinson & Co., Mountain
View, CA), and incubated for another 45 min before sorting on an ATC3000 flow cyto-
meter (ODAM, Wissembourg, France). Aggregated and dead cells were excluded on the
basis of forward angle light scatter values.Results
General Remark. HPI/IL-6 was originally quantified on the basis of its
growth factor activity for B cell hybridoma 7TD1, which requires ^-1 pg/ml for
half-maximal growth. It later turned out that the sensitivity of 7TD1 was much
higher than that of other HPl/IL-6-dependent cell lines. Plasmacytomas, for
example, require ^-100 times more HPI/IL-6 than the hybridoma cell line (2).
It should therefore be kept in mind that, as a result of this unusual sensitivity,
hybridoma growth factor units of HPI/IL-6 may be misleadingly high.
Proliferation ofPeripheral T Cells in Response to HP11IL-6.
￿
HPI/IL-6 purified
to homogeneity from the supernatant of helper T cell clone TUC2 .15 was found
to induce a 100-fold increase in the proliferation of spleen cells exposed to sub-
mitogenic doses of PHA (Table I, Exp. 1). This response, which was quantita-
tively similar to that induced by IL-2 and IL-4, was saturable and required
^-100 hybridoma growth factor units per milliliter for half-maximal stimulation.
The proliferation induced by HPI/IL-6 was completely abolished after treat-
ment with anti-Thy-1 antibody and complement, demonstrating the T cell nature
of the responding cells (Table I, Exp. 1). Cell sorting experiments indicated that
both the L3T4 + and the Lyt-2+ subsets participated in this response (Fig. 1) .
TUC2.15 supernatant contains no detectable IL-2 but considerable amounts
of IL-4. Therefore, we were concerned that in spite of its apparent homogeneity
in silver-stained SDS polyacrylamide gels, our HPI/IL-6 preparation might still
contain traces of this lymphokine that could be responsible for the observed T
TABLE I





* 5 X 10" spleen cells were stimulated with PHAandtheindicatedcytokines as describedin Materials
and Methods. Thymidine incorporation was measured on day 4 (mean of triplicate measurements
in cpm, SE <I09'0).





1 None 160 865 124
HPI/IL-6 80 224 19,476 103
400 320 80,528 151
2,000 297 86,751 200
IL-2 0.8 313 11,193 356
4 771 58,303 1,000
20 1,270 72,224 1,208
100 1,862 77,022 1,189
IL-4 4 435 3,771 471
20 662 26,528 822
100 654 55,998 760
2 None 259 553
L-HGF 2,000 777 52,7851420
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cell growth factor activity . Evidence against this possibility was provided by the
following observations : (a) hybridoma growth factor purified from supernatants
of L cells (L-HGF), which produce no IL-4, was as active as HP1/IL-6 (Table I,
Exp . 2), and (b) anti-IL-4 mAb 111111, which completely inhibited the prolifer-
ative response of T cells to IL-4, had no effect on their response to HPI/IL-6
(Fig . 2) . The involvement of other contaminants was ruled out by the observa-
tion that anti-HPI/IL-6 mAb 6B4 completely and specifically abolished the
HP1/IL-6-induced T cell proliferation (Fig . 2) .
Proliferation of Thymocytes in Response to HPI1IL-6 .
￿
In the presence of PHA,
HPI/IL-6 induced thymocyte proliferations that were 5-10 times stronger than
those obtained with IL-1 (Table II). This observation, together with the fact that
IL-1 is a potent inducer of IL-6 in human fibroblasts (9), prompted us to exam-
ine the possible involvement of HPI/IL-6 in the response of thymocytes
to IL-1 . Anti-HPI/IL-6 mAb 6114, which completely blocked the proliferation
of thymocytes induced by HPI/IL-6, had, however, no significant effect on the
IL-1-induced proliferation (Table III), indicating that thymocyte activation by
IL-1 is probably not mediated by HPI/IL-6 . In this context, it is noteworthy





















FIGURE 1 . T cell subsets responsive to HPI/IL-6 .
Unsorted spleen cells or sorted L3T4+ and Lyt-2+
splenic T cell subpopulations (both 96-97% pure) were
incubated with (shaded bars) or without (open bars) HPI/
IL-6 (10' U/ml) in the presence of a submitogenic dose
of PHA (1/2,000 for unsorted and L3T4+ cells and 1/
4,000 for Lyt-2+ cells) . Thymidine incorporation was
measured on day 4 (mean of triplicate measurements, 1
SE) .
FIGURE 2 . Inhibition of T cell proliferation by anti-
HP1/IL-6 and anti-IL-4 mAbs . PHA-activated spleen
cells were incubated with HPI/IL-6 (2 X 10 3 U/ml, o),
IL-2 (50 U/ml, A) or IL-4 (50 U/ml, A), and increasing











mAbs . Thymidine incorporation was measured on day 4
ANTIBODY CONCENTRATION (pg/ml)
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Optimal numbers of thymocytes (1 .5 X 106 cells/well for IL-1 and0.5 X
10' cells/well for HPI/IL-6) were cultured in the presence of PHA (1/
500) andof theindicateddoses ofcytokines.Thymidineincorporation was
measured on day 3 after a 6-h pulse (mean of triplicate cultures, SE
<10%).
of IL-2 secretion by T cell lymphoma LBRM-33-A15 (25) or on the induction
of the response of unstimulated thymocytes to IL-2 (26) (data not shown).
Profound differences were observed in the responses of individual thymocyte
subsets to HPI/IL-6. Immature L3T4+,Lyt-2 + cells, which proliferated signifi-
cantly although more weakly than the mature cells in the presence ofIL-2, were
TABLE III
Anti-HP1 6B4 mAb Inhibits HPI/IL-6- but not IL-1-induced
ThymocyteProliferation
Proliferation of PHA-activated thymocytes was measured on day 3. Con-
trol cultures were incubatedwithout antibody. Results were calculated as
follows: 100 X [(cpmwith PHA, cytokine,and antibody)- (cpm with PHA

































10 -1 .5 90.2
30 -4.0 91.31422
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FIGURE 3 .
￿
Differential response of thymocyte subpop-
ulations to HPI/IL-6 and IL-2 . Proliferation of PHA-
activated thymocyte subpopulations in control (open bars)
cultures and in cultures stimulated with HPI/IL-6 (10"
U/ml, shaded bars) or IL-2 (100 U/ml, solid bars) . Thy-
midine incorporation was measured on day 3 (mean
of triplicate cultures, 1 SE). Sorted L3T4+Lyt-2+ ,
L3T4+ Lyt2- , L3T4- Lyt-2+ thymocytes were 95%, 98%,
and 98% pure, respectively .
totally unresponsive to HP1/IL-6, whereas mature L3T4+,Lyt-2- and
L3T4 -,Lyt-2+ cells responded equally well to both cytokines (Fig. 3) .
Proliferation of Accessory Cell-depleted T Cells in Response to HP11IL-6.
￿
To
examine the possible involvement of accessory cells in the responses to HP1/IL-
6, we purified mesenteric T cells by sequential passages over nylon-wool col-
umns and treatment with anti-la antibodies and complement . The cells collected
at various stages of this procedure were then stimulated, in the presence or
absence of HPOL-6, with a concentration of Con A that yielded maximal pro-
liferation of unfractionated cells . The population obtained after two nylon-wool
passages and two anti-Ia treatments, which consisted of >98% Thy-1 + cells, and
contained <0.2% accessory cells by nonspecific esterase staining, was totally
unresponsive to this dose of Con A, indicating a rigorous depletion of accessory
cells (27, 28). As shown in Table IV, the response of these cells to Con A was
almost completely restored upon addition of HP1/IL-6 . Likewise, the synergistic
activation of T cells by HPI/IL-6 and PHA or insolubilized anti-T3 antibodies
TABLE IV
Proliferation ofAccessory Cell-depleted TCells in Response to HP1/IL-6 and Various TCell
Stimuli
Treatmentof
Mesenteric lymph node cells were fractionated by one or two passages over nylon-wool columns fol-
lowed by one or two treatments with anti-Ia antibodies andcomplement . They were then incubated
(5 X 104/well) with or without 103 U/ml of HPI/IL-6 in the presence of the indicated costimuli .











- - None 463 1010
Con A* 71,846 146,280
Once - ConA 37,658 143,690
Twice - Con A 15,720 104,397
Twice Once ConA 241 92,507
Twice Twice Con A 58 90,653
PHA$ 449 124,320




Failureof Helper TCell Lines to Respond to HP1/IL-6
Tcells from 2-wk-old cultures (5 X 10' cells/well) were incubated for 2 d
with IL-2,IL-4 (100 U/ml each), or HP1/IL-6 (10' U/ml) andpulsed with
thymidine(0.5 pCi/well) for6h. Blasts were obtained by a 24-h incubation
with antigenand feeder cells.
was also unaffected by accessory cell depletion (Table IV). Similar results were
obtained with splenic T cells prepared by the same procedure (data not shown).
Lack of Response ofHelper T Cell Lines to HP11IL-6.
￿
The proliferation of sev-
eral helper T cell lines in the presence of HP1/IL-6 was compared with the
TABLE VI
Stimulation by HP1/IL-6 and IL-2 of Cytolytic T Cell Responses
In Vitro
C57BL/6 spleen cells (2 X 106) were stimulated with 2 X 106 irradiated
DBA/2 high-density spleen cells in the presence of HP1/IL-6 (10' U/ml)
or IL-2 (100 U/ml) as describedin Materialsand Methods. Cytolytic activ-
itywas measured on day 6 using 2,000 "Cr-labeled P815 or EL4 target
cells. Results areexpressed in lyticunits perculture, oneunit correspond-







TUC2.15 3.7 195 117 5.5
TUC5.37 0.3 140 2.1 0.1
TUC7.5 0.1 172 0.3 0.1
TUC7.8 0.4 50 0.3 0.1
TUC7.19 0.1 168 0.6 0.1
TUC7.29 0.1 133 0.2 0.1
TUC7.33 0.2 142 105 0.1
TUC7.37 0.1 161 6.5 0.6
TUC7.52 0.1 56 0.1 0.2
TUC7.58 0.2 135 1.3 0.2
TUC13 1.8 133 8.9 2.2
TUC7.51 rested 0.1 81 0.4 0.1






1 None 53 10 <10
HP1/IL6 78 814 <10
IL2 100 2,491 53
2 None 50 8 NT
HP1/IL6 90 1,140 NT
IL2 145 6,300 NT1424
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responses obtained with IL-2 and IL-4 (Table V). In the absence of any other
s tested proliferated extensively in response to IL-2, but
none responded to HPI/IL-6. The responses to IL-4 were intermediate, with
about half the lines proliferating significantly and two showing extensive prolif-
eration. Costimulation with PHA or the use of biastic rather than resting cells
increased the responses to IL-4 but failed to induce any response to HPI/IL-6.
Stimulation of Cytolytic T Cell Differentiation by HPIfIL-6. The T cell re-
sponses to HPI/IL-6 examined so far were exclusively of proliferative nature.
To evaluate the ability of HPI/IL-6 to also induce T cell differentiation, we
tested its influence on the development of a primary in vitro cytolytic T cell
response. As shown in Table VI, HPI/IL-6 enhanced the primary anti-H-2d
cytolytic response of C57BL/6 spleen cells ^-100-fold with little effect on cell
recoveries. These responses were extremely specific, indicating that HPIfIL-6
stimulated the differentiation of only those CTL precursors that had been acti-
vated by a specific interaction with antigen.
Discussion
HPI/IL-6, the murine hybridoma and plasmacytoma growth factor, was
found to stimulate the proliferation of mature thymic and peripheral T cells in
the presence of submitogenic doses of either PHA or anti-T cell receptor anti-
bodies. Both the L3T4+ and the Lyt-2+ T cell subsets responded to this st
lation, which was completely inhibitable by an anti-HPI/I1.-6 mAb and did
apparently not require accessory cells. In addition, primary allogeneic cytolytic
T cell responses were also enhanced in the presence of HPI/11,6.
Half-maximal proliferation of mature T cells was induced with -100 pg/ml
of HPI/IL-6, which is well within the physiological range, since titers equivalent
to 100 ng/ml have been detected in the serum of mice injected with endotoxin
(29). This concentration is -10 times lower than that required for half-maximal
stimulation of normal B cells (14), which suggests that in spite of the original
identification of HPI/IL-6 as a growth factor for transformed B cells, the pri-
mary immunological target of this molecule may be the T rather than the B
lymphocyte. The observation that B cells, unlike T cells, require costimulation
with IL-1 to become fully responsive to HPI/IL-6 (14) would also seem to sup-
port this idea.
T cell activation by lectins requires the presence of accessory cells (27, 28).
The observation that HPI/IL-6 could restore the response of accessory cell-
depleted T cells to Con A suggests that production of this molecule by macro-
phages (3, 29) plays a significant role in the ability of these cells to support such
responses, and raises the question of the relation between HPI/IL-6 and
recently described accessory cell-replacing factors (30, 31) . The mechanisms
ed in T cell activation by HPI/IL-6 have not yet been fully clarified. Pre-
liminary experiments using anti-IL-2-R antibodies suggest that HPI/IL-6 could
operate by inducing the production of IL-2 (manuscript in preparation). How-
ever, we have not been able so far to detect any IL-2 in the supernatant of HPI/
IL-6-activated T cells.
The response of PHA-activated peripheral T cells to HPI/IL-6 was quantita-UYTrENHOVE ET AL.
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tively similar to that obtained with IL-2 and usually better than that induced by
IL-4. Several observations, however, indicate that T cells are less uniformly
responsive to HP1/IL-6 than to IL-2. Indeed, certain T cell subsets, such as
immature thymocytes, were totally unresponsive to HP1/IL-6 under conditions
where they significantly responded to IL-2. Moreover, all our helper T cell
clones or lines failed to proliferate in the presence of HP1/IL-6, suggesting that
cells repeatedly activated by exposure to antigen, which in our hands become
increasingly responsive to IL-2 and IL-4, lose their responsiveness to HP1/IL-
6. This observation suggests that, unlike IL-2, HP1/IL-6 may primarily act dur-
ing the initial stages of T cell activation, which would be consistent with the
finding that the number of IL-6 receptors is higher on resting than on activated
human T cells (32). Considering the wide variety of cells both within (e.g., mac-
rophages) and outside (e.g., fibroblasts) the immune system (3, 4) that can be
induced to produce HP1/IL-6 by viral infections or exposure to endotoxin, it
is tempting therefore to speculate that this molecule could play a unique role in
initiating T cell responses by enabling cells that do not belong to the immune
system to activate T cells directly.
Summary
Interleukin-HP1 (HP1)/IL-6 is a 25-30-kD protein produced by macro-
phages, fibroblasts, and certain T cell lines. It was originally identified as a
mouse growth factor for B cell hybridomas and plasmacytomas, and was recently
shown to stimulate growth and differentiation of normal B cells. Here we dem-
onstrate that, in the presence of lectins or anti-T cell receptor antibodies, HP1/
IL-6 has a growth factor activity equivalent to that of IL-2 for mature thymic
and peripheral T cells of both the L3T4+ and Lyt-2+ subsets. Contrary to IL-2
and IL-4, HP1/IL-6 was, however, not capable of supporting the growth of
established T cell lines. In addition to its effects on T cell proliferation, HP1/
IL-6 also enhanced the differentiation of mouse cytolytic T cell precursors in
primary allogeneic mixed lymphocyte cultures.
Fractionation of responding cell populations indicated that HP1/IL-6 was
capable of restoring the response of accessory cell-depleted T cells to Con A.
This observation suggests that the production of HP1/IL-6 by macrophages
could, at least partly, explain their role in polyclonal T cell activation.
We thank Dr. D. Godelaine for helpful discussions; Drs. W. E. Paul, P. Lomedico, W.
Fiers, O. Leo, and H Bazin for the gift of reagents; P. Wauters for running the flow
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Note added in proof Garman et al. (33) have recently shown that human IL-6 induces
proliferation of mouse T cells and that this proliferation can be inhibited by anti-IL-2-R
antibodies.
References.
1 . Van Snick, J., S . Cayphas, A. Vink, C. Uyttenhove, P. G. Coulie, and R. J. Simpson.
1986. Purification and NH2-terminal amino acid sequence of a new T-cell-derived1426
￿
T CELL ACTIVATION BY INTERLEUKIN-HP1/IL-6
lymphokine with growth factor activity for B cell hybridomas. Proc. Nail. Acad. Sci.
USA. 83 :9679.
2 . Van Snick, J., A. Vink, S. Cayphas, and C. Uyttenhove. 1987. Interleukin-HP1, a T
cell-derived hybridoma growth factor that supports the in vitro growth of murine
plasmacyyomms. J. Exp. Med. 165:641 .
3 . Nordan, R. P., and M. Potter. 1986. A macrophage-derived factor required by plas-
macytomas for survival and proliferation in vitro. Science (Wash. DC). 233:566.
4. Cayphas, S., J. Van Damme, R. J. Simpson, A. Billiau, and J. Van Snick. 1988. Iden-
tification of an interleukin-HPI-like plasmacytoma growth factor produced by L
cells in response to viral infection. J. Immunol.139:2965 .
5. Nordan, R. P., J. P. Pumphrey, and S. Rudikoff. 1987. Purification and NH2-ter-
minal sequence of a plasmacytoma growth factor derived from the murine macro-
phage cell line, P388D1 . J. Immunol. 139:813.
6. Van Snick, J ., S. Cayphas, J. P. Szikora, J. C. Renauld, E. Van Roost, T. Boon, and
R. Simpson. 1988. cDNA cloning of murine interleukin-HP1 : homology with human
interleukin 6. Eur. J. Immunol. 18:193.
7. Poupart, P., P. Vandenabeele, S. Cayphas, J. Van Snick, G. Haegeman, V. Kruys, W.
Fiers, and J. Content. 1987 . B cell growth modulating and differentiating activities
of recombinant human 26-kd protein. EMBO (Eur. Mol. Biol. Organ.) J. 6:1219.
8. Brakenhoff, J. P. J., E. R. de Groot, R. Evers, H . Pannekoek, and L. A. Aarden.
1988. Molecular cloning and expression of hybridoma growth factor in Escherichia
coli. J. Immunol. 139:4116.
9. Van Damme, J., G. Opdenakker, R. J . Simpson, M. R. Rubira, S. Cayphas, A. Vink,
A. Billiau, and J. Van Snick. 1987 . Identification of the human 26-kD protein, inter-
feron-/32, as a B cell hybridoma/plasmacytoma growth factor inducible by interleukin
1 and tumor necrosis factor. J. Exp. Med. 165 :914 .
10. Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashi-
wamura, K. Nakajima, K. Koyama, A. Iwamatsu, S. Tsunasawa, F. Sakiyama, H. Mat-
sui, Y. Takahara, T. Taniguchi, and T. Kishimoto. 1986. Complementary DNA for a
novel human interleukin (BSF-2) that induces B lymphocytes to produce immuno-
globulin. Nature (Lond.). 324:73.
11 . Haegeman, G., J. Content, G. Volckaert, R. Derynck, J. Tavernier, and W. Fiers.
1986. Structural analysis of the sequence coding for an inducible 26-kDa protein in
human fibroblasts. Eur. J. Biochem. 159:625.
12 . Zilberstein, A., R. Ruggieri, J. H. Korn, and M. Revel. 1986. Structure and expres-
sion of :DNA and genes from human interferon-(32, a distinct species inducible by
growth regulatory cytokines. EMBO (Eur. Mol. Biol. Organ.) J. 5 :2529.
13. Gauldie, J., C. Richards, D . Harnish, P. Lansdorp, and H. Baumann. 1987. Inter-
feron a2/B cell stimulatory factor 2 shares identity with monocyte-derived hepato-
cyte-stimulating factor and regulates the major acute phase protein response in liver
cells. Proc. Nail. Acad. Sci. USA. 84:7251 .
14. Vink, A., P. G. Coulie, P. Wauters, R. P. Nordan, and J. Van Snick. 1988. B cell
growth and differentiation activity of interleukin-HP1 and related plasmacytoma
growth factors. Synergy with interleukin 1 . Eur. J. Immunol. In press.
15. Julius, M. H., E. Simpson, and L. A. Herzenberg. 1973 . A rapid method for the
isolation of functional thymus-derived murine lymphocytes. Eur. J. Immunol. 3:645.
16. Kappler, J. W. B. Skidmore, J. White, and P. Marrack. 1981 . Antigen-inducible, H-
2-restricted, interleukin-2-producing T cell hybridomas. J. Exp. Med. 153 :1198.
17. Gubler, U., A. O. Chua, A. S. Stern, C. P. Hellmann, M. P. Vitek, T. M. Dechiara,
W. R. Benjamin, K. J. Collier, M. Dukovich, P. C. Familletti, C. Fiedler-Nagy, J .
Jenson, K. Kaffka, P. L. Killian, D. Stremlo, B. H. Wittreich, D. Woehle, S. B. Mizel,UYTTENHOVE ET AL.
￿
1427
and P. T. Lomedico. 1986. Recombinant human interleukin la: purification and
biological characterization. J. Immunol. 136:2492.
18 . Devos, R., G. Plaetinck, H. Cheroutre, G. Simons, W. Degrave, J. Tavernier, E.
Remaut, and W. Fiers. 1983. Molecular cloning of human interleukin 2 cDNA and
its expression in E. coli. Nucleic Acids Res. 11 :4307.
19. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978 . T cell growth factor: param-
eters of production and a quantitative microassay for activity. J. Immunol. 120:2027.
20. Ohara, J., and W. E. Paul. 1985. Production of a monoclonal antibody to and molec-
ular characterization of B cell stimulatory factor-1 . Nature (Lond.). 315:333.
21 . Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, and J. A. Bluestone. 1987. Identifi-
cation of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl.
Acad. Sci. USA. 84:1374.
22. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M.
Pierres, and F. Fitch. 1983. Characterization of the murine T cell surface molecule,
designated L3T4, identified by a monoclonal antibody GK1 .5: similarity of L3T4 to
the human LEU-3/T4 molecule. J. Immunol. 131 :2445.
23. Ledbetter, J. A., and L. A. Herzenberg. 1979. Xenogeneic monoclonal antibodies
to mouse lymphoid differentiation antigens. Immunol. Rev. 47:63.
24. Bazin, H., L-M. Xhurdebise, G. Burtonboy, A-M. Lebacq, L. De Clercq, and F. Cor-
mont. 1984. Rat monoclonal antibodies. 1. Rapid purification from in vitro culture
supernatants. J. Immunol. Methods. 66:261 .
25. Conlon, P. J. 1983. A rapid biologic assay for the detection of interleukin 1 . J. Immu-
nol. 131 :1280.
26. Mannel, D. N., S. B. Mizel, T. Diamantstein, and W. Falk. 1985. Induction of inter-
leukin 2 responsiveness in thymocytes by synergistic action of interleukin 1 and
interleukin 2. J. Immunol. 134:3108.
27 . Habu, S., and M. Raff. 1977. Accessory cell dependence of lectin-induced prolifer-
ation of mouse T lymphocytes. Eur. J. Immunol. 7:451 .
28 . Raulet, D. H., T. Hiinig, and D. C. Parker. 1982. T cells produce TRF in response
to ConA and factors in T cell hybridoma supernatants. J. Immunol. 128:908.
29 . Coulie, P. G., S. Cayphas, A. Vink, C. Uyttenhove, and J. Van Snick. 1987. Interleu-
kln-HPI-related hybridoma and plasmacytoma growth factors induced by lipopoly-
saccharide in vivo. Eur. J. Immunol. 17:1217.
30. Garman, R. D., and D. H. Raulet. 1987. Characterization of a novel murine T cell-
activating factor. J. Immunol. 138:1121 .
31 . Hardt, C., S. Nobuko, and H. Wagner. 1987. Functional and biochemical charac-
teristics of a murine interleukin 2 receptor-inducing factor. Eur. J. Immunol. 17:209.
32 . Taga, T., Y. Kawanishi, R. R. Hardy, T. Hirano, and T. Kishimoto. 1987. Receptors
for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation
of their expression. J. Exp. Med. 166:967.
33 . Garman, R. D., K. A. Jacobs, S. C. Clark, and D. H. Raulet. 1987. B-cell stimulatory
factor 2 (#2 interferon) functions as a second signal for interleukin 2 production by
mature murine T cells. Proc. Natl. Acad. Sci. USA. 84:7629.